139 related articles for article (PubMed ID: 10674004)
21. Differences in kinetic properties of pure recombinant human and mouse deoxycytidine kinase.
Johansson M; Karlsson A
Biochem Pharmacol; 1995 Jul; 50(2):163-8. PubMed ID: 7632159
[TBL] [Abstract][Full Text] [Related]
22. Stratification of nucleoside analog chemotherapy using 1-(2'-deoxy-2'-18F-fluoro-β-D-arabinofuranosyl)cytosine and 1-(2'-deoxy-2'-18F-fluoro-β-L-arabinofuranosyl)-5-methylcytosine PET.
Lee JT; Campbell DO; Satyamurthy N; Czernin J; Radu CG
J Nucl Med; 2012 Feb; 53(2):275-80. PubMed ID: 22302964
[TBL] [Abstract][Full Text] [Related]
23. Nucleotide specificity of human deoxycytidine kinase.
Shewach DS; Reynolds KK; Hertel L
Mol Pharmacol; 1992 Sep; 42(3):518-24. PubMed ID: 1406603
[TBL] [Abstract][Full Text] [Related]
24. Comparison of cytotoxicity of 2-chloro- 2'-arabino-fluoro-2'-deoxyadenosine (clofarabine) with cladribine in mononuclear cells from patients with acute myeloid and chronic lymphocytic leukemia.
Lindemalm S; Liliemark J; Gruber A; Eriksson S; Karlsson MO; Wang Y; Albertioni F
Haematologica; 2003 Mar; 88(3):324-32. PubMed ID: 12651272
[TBL] [Abstract][Full Text] [Related]
25. Quantitation of synergism of arabinosylcytosine and cladribine against the growth of arabinosylcytosine-resistant human lymphoid cells.
Han T; Fernandez M; Chou TC; Agarwal RP
J Cancer Res Clin Oncol; 2005 Sep; 131(9):609-16. PubMed ID: 16044347
[TBL] [Abstract][Full Text] [Related]
26. Substrate/inhibitor specificities of human deoxycytidine kinase (dCK) and thymidine kinases (TK1 and TK2).
Kierdaszuk B; Krawiec K; Kazimierczuk Z; Jacobsson U; Johansson NG; Munch-Petersen B; Eriksson S; Shugar D
Adv Exp Med Biol; 1998; 431():623-7. PubMed ID: 9598140
[TBL] [Abstract][Full Text] [Related]
27. Intracellular pharmacodynamic studies of the synergistic combination of 6-mercaptopurine and cytosine arabinoside in human leukemia cell lines.
Ramilo-Torno LV; Avramis VI
Cancer Chemother Pharmacol; 1995; 35(3):191-9. PubMed ID: 7805176
[TBL] [Abstract][Full Text] [Related]
28. Phosphorylation of deoxycytidine kinase on Ser-74: impact on kinetic properties and nucleoside analog activation in cancer cells.
Amsailale R; Van Den Neste E; Arts A; Starczewska E; Bontemps F; Smal C
Biochem Pharmacol; 2012 Jul; 84(1):43-51. PubMed ID: 22490700
[TBL] [Abstract][Full Text] [Related]
29. Docking simulation with a purine nucleoside specific homology model of deoxycytidine kinase, a target enzyme for anticancer and antiviral therapy.
Johnsamuel J; Eriksson S; Oliveira M; Tjarks W
Bioorg Med Chem; 2005 Jul; 13(13):4160-7. PubMed ID: 15876539
[TBL] [Abstract][Full Text] [Related]
30. Relationship between cladribine (CdA) plasma, intracellular CdA-5'-triphosphate (CdATP) concentration, deoxycytidine kinase (dCK), and chemotherapeutic activity in chronic lymphocytic leukemia (CLL).
Albertioni F; Lindemalm S; Eriksson S; Juliusson G; Liliemark J
Adv Exp Med Biol; 1998; 431():693-7. PubMed ID: 9598154
[TBL] [Abstract][Full Text] [Related]
31. [Relationship between the expression of the genes encoding the key enzymes for cytarabine metabolism and the pharmacokinetics of cytarabine in the treatment of childhood acute leukemia with high-dose cytarabine].
Xie XT; Jiang SY; Li BS; Yang LL
Zhonghua Er Ke Za Zhi; 2008 Apr; 46(4):276-80. PubMed ID: 19099730
[TBL] [Abstract][Full Text] [Related]
32. The structure of human deoxycytidine kinase in complex with clofarabine reveals key interactions for prodrug activation.
Zhang Y; Secrist JA; Ealick SE
Acta Crystallogr D Biol Crystallogr; 2006 Feb; 62(Pt 2):133-9. PubMed ID: 16421443
[TBL] [Abstract][Full Text] [Related]
33. Substrate/inhibitor properties of human deoxycytidine kinase (dCK) and thymidine kinases (TK1 and TK2) towards the sugar moiety of nucleosides, including O'-alkyl analogues.
Kierdaszuk B; Krawiec K; Kazimierczuk Z; Jacobsson U; Johansson NG; Munch-Petersen B; Eriksson S; Shugar D
Nucleosides Nucleotides; 1999 Aug; 18(8):1883-903. PubMed ID: 10478487
[TBL] [Abstract][Full Text] [Related]
34. Selective increase of dATP pools upon activation of deoxycytidine kinase in lymphocytes: implications in apoptosis.
Keszler G; Spasokoukotskaja T; Csapo Z; Virga S; Staub M; Sasvari-Szekely M
Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1335-42. PubMed ID: 15571254
[TBL] [Abstract][Full Text] [Related]
35. Resistance to 2-chloro-2'-deoxyadenosine of the human B-cell leukemia cell line EHEB.
Cardoen S; Van Den Neste E; Smal C; Rosier JF; Delacauw A; Ferrant A; Van den Berghe G; Bontemps F
Clin Cancer Res; 2001 Nov; 7(11):3559-66. PubMed ID: 11705877
[TBL] [Abstract][Full Text] [Related]
36. Increased ratio between deoxycytidine kinase and thymidine kinase 2 in CLL lymphocytes compared to normal lymphocytes.
Nielsen SE; Munch-Petersen B; Mejer J
Leuk Res; 1995 Jul; 19(7):443-7. PubMed ID: 7637389
[TBL] [Abstract][Full Text] [Related]
37. Expression of deoxycytidine kinase in leukaemic cells compared with solid tumour cell lines, liver metastases and normal liver.
van der Wilt CL; Kroep JR; Loves WJ; Rots MG; Van Groeningen CJ; Kaspers GJ; Peters GJ
Eur J Cancer; 2003 Mar; 39(5):691-7. PubMed ID: 12628850
[TBL] [Abstract][Full Text] [Related]
38. Increased deoxycytidine kinase activity by etoposide in L1210 murine leukemic cells.
Ooi K; Ohkubo T; Higashigawa M; Kawasaki H; Sakurai M
Biol Pharm Bull; 1996 Oct; 19(10):1382-3. PubMed ID: 8913519
[TBL] [Abstract][Full Text] [Related]
39. Deoxycytidine kinase can be also potentiated by the G-protein activator NaF in cells.
Staub M; Csapó Z; Spasokukotskaja T; Sasvári-Székely M
Adv Exp Med Biol; 1998; 431():425-8. PubMed ID: 9598103
[TBL] [Abstract][Full Text] [Related]
40. Activation of deoxycytidine kinase during inhibition of DNA synthesis in human lymphocytes.
Sasvári-Székely M; Csapó Z; Spasokoukotskaja T; Eriksson S; Staub M
Adv Exp Med Biol; 1998; 431():519-23. PubMed ID: 9598121
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
